Dataset for "Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice"

Bourbon virus (BRBV) is an emerging tick-borne pathogen that causes severe, often fatal illness marked by cytopenia and thrombocytopenia. With no approved therapies or vaccines, treatment options remain limited. Using a preclinical mouse model, we evaluated molnupiravir, a broad-spectrum antiviral approved in the U.S. Molnupiravir reduced viral replication in cells and tissues, improved survival, and alleviated disease signs. These results highlight its potential as a therapeutic candidate for BRBV infection.